A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants With Post-Traumatic Stress Disorder (PTSD)

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 10 Apr 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

06 Apr 2023 Status changed from active, no longer recruiting to discontinued on company's decision.
31 Mar 2023 Status changed from recruiting to active, no longer recruiting.
27 Feb 2023 According to an Aptinyx media release, company intends to undertake cost-cutting measures, and company will terminate its ongoing Phase 2b study of NYX-783 in PTSD and analyze data to date to inform the next steps for the program.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com